The clinical benefit of adjuvant BCG instillations in the bladder could result from a local inflammatory response, which could contribute to either increase the frequency of existing tumor-specific CD8+ cytolytic T cells or prime new ones. The gene discussed is CD8A; the disease is neoplasm.